Wednesday, May 07, 2025 2:10:15 PM
My man I really hate these boards but the break up value of Nwbo is 3x the price it is now fully diluted which is .90 a share give or take. June 8 is a presentation at New York academy of science given by our coo Marnix Bosch ( who is very intelligent and a great speaker , I’ve met him several times ). The title is Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Response.we know by the title they are going to present new data not old rehashed shit. So I think the next big move is June 8th ( I think that’s the date).
Since the "Next Gen" DCVax is not in the clinic, what he will present will be some descriptive info, ex-vivo assays and maybe mice data. That does nothing for the market. It is good to see NWBO shift focus to something not from the 20'th century though.
As far as NYAS as a site. That is huge. Clearly that alone insures a nice reaction. How could it not?
As far as 3x breakup value, that is a joke. Outside of -L value they have virtually zero.
. The Direct program that is being relaunched and still pre-clinical,
. The Roswell program they recently inlicensed for under a couple million dollars in potential milestones.
. Flaskworks that they picked up for $2M and clearly are having a hard time developing as they had to give up on thir previous attempt to address weaknesses. And it is nothing special, plentty of other automated cell manbufacturing systems exists.
Oh, if you are going to say Sawston, think harder. The GMP facility is under long term sublease to Advent. So that is worth $140k/year. The rest of the building is just a building that they rent.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
